The board of directors of Venus Remedies will meet on Wednesday to consider and approve raising of funds by way of qualified institutional placement. Investors will keenly observe the price, timing and quantum of the QIP issue. The pharma major had reported a loss of ₹2.10 crore for the third quarter ended December 2016 against a loss of ₹25 lakh in the year-ago period. Sales declined to ₹85.36 crore (₹98.42 crore).
Venus Remedies: board meets for QIP
Published on
February 21, 2017 16:10
Tags